TrialsgrambetaRCTs are beautiful

SIRIUS

2014

Mepolizumab as Oral-Corticosteroid-Sparing Therapy

In 135 patients with OCS-dependent severe eosinophilic asthma, mepolizumab 100 mg SC every 4 weeks reduced maintenance oral corticosteroid dose compared with placebo.

Result

OCS-dose reduction
Absolute difference
50 points
NNT
2

Absolute difference and NNT are derived from the event rates.

Also reported: Exacerbations -32%.

Original publication
Subtopic
OCS sparing
Design
RCT
Relevance
Supporting: context rather than must-know.
Source
Bel EH, et al. N Engl J Med. 2014;371(13):1189-1197.doi 10.1056/NEJMoa1403291

Discussion & critique

Made OCS sparing a key indication for anti-IL-5 biologics.